Klaus Pfizenmaier

Klaus Pfizenmaier

Auto-generated profile, based on publicly available information

Klaus Pfizenmaier

Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2005 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
AHAngelika Hausser
Angelika Hausser
PSPeter Storz
Peter Storz
SMSusanne Märtens
Susanne Märtens
GLGisela Link
Gisela Link
ATAlex Toker
Alex Toker
KPKlaus Pfizenmaier
Klaus Pfizenmaier

1 June 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
TETim Eiseler
Tim Eiseler
AHAngelika Hausser
Angelika Hausser
LKLine De Kimpe
Line De Kimpe
JLJohan Van Lint
Johan Van Lint
KPKlaus Pfizenmaier
Klaus Pfizenmaier
We here identify protein kinase D (PKD) as an upstream regulator of the F-actin-binding protein cortactin and the Arp actin polymerization machinery. PKD phosphorylates cortactin in vitro and in vivo at serine 298 thereby generating a 14-3-3 binding motif. In vitro, a phosphorylation-deficient cortactin-S298A protein accelerated VCA-Arp-cortactin-mediated synergistic actin polymerization and showed reduced F-actin binding, indicative of enhanced turnover of nucleation complexes. In vivo, cortactin co-localized with the nucleation promoting factor WAVE2, essential for lamellipodia extension, in the actin polymerization zone in Heregulin-treated MCF-7 cells. Using a 3-dye FRET-based approach we further demonstrate that WAVE2-Arp and cortactin prominently interact at these structures. Accordingly, cortactin-S298A significantly enhanced lamellipodia extension and directed cell migration. Our data thus unravel a previously unrecognized mechanism by which PKD controls cancer cell motility.

26 August 2010 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
BSB Schneider
B Schneider
SMS Münkel
S Münkel
AKA Krippner-Heidenreich
A Krippner-Heidenreich
IGI Grunwald
I Grunwald
WWW S Wels
W S Wels
JGJ Gerspach
J Gerspach
In an attempt to improve TRAIL's (tumor necrosis factor-related apoptosis-inducing ligand) tumor selective activity a variant was designed, in which the three TRAIL protomers are expressed as a single polypeptide chain (scTRAIL). By genetic fusion with a single-chain antibody fragment (scFv) recognizing the extracellular domain of ErbB2, we further equipped scTRAIL with tumor-targeting properties. We studied tumor targeting and apoptosis induction of scFv–scTRAIL in comparison with non-targeted scTRAIL. Importantly, the tumor antigen-targeted scTRAIL fusion protein showed higher apoptotic activity in vitro, with a predominant action by TRAIL-R2 signaling. Pharmacokinetic studies revealed increased plasma half-life of the targeted scTRAIL fusion protein compared with scTRAIL. In vivo studies in a mouse tumor model with xenotransplanted Colo205 cells confirmed greater response to the ErbB2-specific scTRAIL fusion protein compared with non-targeted scTRAIL both under local and systemic application regimen. Together, in vitro and in vivo data give proof of concept of higher therapeutic activity of tumor-targeted scFv–scTRAIL molecules. Further, we envisage that through targeting of scTRAIL, potential side effects should be minimized. We propose that scFv-mediated tumor targeting of single-chain TRAIL represents a promising strategy to improve TRAIL's antitumoral action and to minimize potential unwanted actions on normal tissues.

12 April 2012 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MSM Siegemund
M Siegemund
NPN Pollak
N Pollak
OSO Seifert
O Seifert
KWK Wahl
K Wahl
KHK Hanak
K Hanak
KPK Pfizenmaier
K Pfizenmaier
Although targeting of the death receptors (DRs) DR4 and DR5 still appears a suitable antitumoral strategy, the limited clinical responses to recombinant soluble TNF-related apoptosis inducing ligand (TRAIL) necessitate novel reagents with improved apoptotic activity/tumor selectivity. Apoptosis induction by a single-chain TRAIL (scTRAIL) molecule could be enhanced >10-fold by generation of epidermal growth factor receptor (EGFR)-specific scFv-scTRAIL fusion proteins. By forcing dimerization of scFv-scTRAIL based on scFv linker modification, we obtained a targeted scTRAIL composed predominantly of dimers (Db-scTRAIL), exceeding the activity of nontargeted scTRAIL ∼100-fold on Huh-7 hepatocellular and Colo205 colon carcinoma cells. Increased activity of Db-scTRAIL was also demonstrated on target-negative cells, suggesting that, in addition to targeting, oligomerization equivalent to an at least dimeric assembly of standard TRAIL per se enhances apoptosis signaling. In the presence of apoptosis sensitizers, such as the proteasomal inhibitor bortezomib, Db-scTRAIL was effective at picomolar concentrations in vitro (EC50 ∼2 × 10−12 M). Importantly, in vivo, Db-scTRAIL was well tolerated and displayed superior antitumoral activity in mouse xenograft (Colo205) tumor models. Our results show that both targeting and controlled dimerization of scTRAIL fusion proteins provides a strategy to enforce apoptosis induction, together with retained tumor selectivity and good in vivo tolerance.

1 April 2008 in Journal of Immunotherapy
Verified
Journal Article
Closed access
RKRoland E. Kontermann
Roland E. Kontermann
SMSabine Münkel
Sabine Münkel
JNJens Neumeyer
Jens Neumeyer
DMDafne Müller
Dafne Müller
MBMarcus Branschädel
Marcus Branschädel
KPKlaus Pfizenmaier
Klaus Pfizenmaier
Tumor necrosis factor (TNF) is a recognized pathogenic mediator in a number of chronic and acute inflammatory diseases. Antibodies targeting TNF have significantly improved therapy of chronic inflammatory diseases, in particular rheumatoid arthritis. Despite this success, anti-TNF treatment shows clinical efficacy only in part of the patients and is often transient, necessitating the development of alternative reagents to combat TNF action. We here describe humanization and functional properties of a TNFR1-specific, monovalent antibody fragment, designated IZI-06.1, which binds to the cysteine-rich domain 1 of TNFR1 with high affinity and competes ligand binding. IZI-06.1 serves as a receptor-selective inhibitor of proapoptotic and antiapoptotic TNF actions, revealed from complete blockage of TNFR1-dependent apoptosis and interleukin-6 induction in Kym 1 and HeLa cells, respectively, whereas TNFR2-mediated signals remained intact, evident from TNF and interleukin-2–mediated costimulation of interferon-γ production in T cells. Accordingly, IZI-06.1 is a TNFR1-selective TNF antagonist and holds great promise to be developed into a clinically applicable therapeutic. IZI-06.1 could be a useful therapeutic alternative in all diseases already known to clinically respond to anti-TNF treatment and particularly in those diseases, where anti-TNF treatment has failed because of complete blockade of TNF action.

29 July 2005 in Cell Death & Differentiation
Verified
Journal Article
Closed access
JGJ Gerspach
J Gerspach
DMD Müller
D Müller
SMS Münkel
S Münkel
OSO Selchow
O Selchow
JNJ Nemeth
J Nemeth
KPK Pfizenmaier
K Pfizenmaier